ONC BeOne Medicines (ONC) Q4 FY25 earnings call
BeOne Medicines concluded 2025 with strong financial results, driven by BRUKINSA's continued global leadership and significant revenue growth. The company achieved GAAP profitability and robust free cash flow, while strategically advancing a diverse pipeline across hematology, solid tumors, and emerging immunology assets. Management is focused on deepening its CLL franchise with next-generation therapies and expanding its oncology footprint, supported by a re-engineered R&D engine.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ONC operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Employees | <12KAnd on behalf of everyone here, I really want to thank the broader oncology community, the patients and families who inspire our work, the clinicians who partner with us every day and our almost 12,000 employees all around the world who continue to raise the bar.Source: earnings call transcript | 12K+I really want to thank the patients and the families that we serve, our physicians and our partners and our more than 12,000 colleagues and their families who focus and urgency make our progress possible.Source: earnings call transcript | 12K+And we do want to just take a moment to thank the patients, their families that we're serving, the physicians, our partners and our more than 12,000 colleagues and their families who focus with urgency every day to make this progress possible.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.